The Hidden Heart Risk You Didn't Know You Had: Lp(a) Explained
Did you know that nearly 20% of the population may be harboring a hidden cholesterol particle that significantly increases their risk of heart attacks and strokes? This often-overlooked culprit is called lipoprotein(a), or Lp(a). Unlike typical cholesterol, Lp(a) is largely determined by genetics and can be dangerously high without any warning signs. In this article, we answer key questions about Lp(a) based on groundbreaking research that analyzed over 20,000 patients.
1. What is lipoprotein(a) and how does it differ from other cholesterol?
Lipoprotein(a), abbreviated as Lp(a), is a type of low-density lipoprotein (LDL) cholesterol with an extra protein called apolipoprotein(a) attached. This structural difference makes it stickier and more likely to accumulate in artery walls, promoting plaque formation. Unlike regular LDL, Lp(a) levels are almost entirely genetically determined and are not influenced much by diet, exercise, or common cholesterol-lowering medications like statins. It also has pro-inflammatory and pro-thrombotic properties, meaning it can promote blood clots and inflammation, compounding cardiovascular risk. For most people, Lp(a) remains a hidden factor because it doesn't show up in standard cholesterol tests.
2. Why is high Lp(a) considered a hidden risk?
Elevated Lp(a) is often called a silent risk factor because most people have no symptoms or obvious warning signs. They may have normal LDL cholesterol and blood pressure levels and feel perfectly healthy. The condition goes undetected until a serious cardiovascular event like a heart attack or stroke occurs. Routine health screenings do not include Lp(a) measurement, so many individuals are unaware they carry this dangerous cholesterol particle. Experts emphasize that a simple blood test can uncover this hidden risk, yet it is rarely ordered unless there is a strong family history of early heart disease or unexplained high cholesterol.
3. How common is elevated Lp(a) according to recent research?
Researchers analyzing data from over 20,000 patients found that approximately one in five individuals has elevated Lp(a) levels. This prevalence is more common than many realize, yet awareness remains low. The frequency varies by ethnicity: it is higher among African Americans and South Asians, and slightly lower in Caucasians and East Asians. Because it is inherited, family members of those with high Lp(a) are also at increased risk. Despite affecting a significant portion of the population, Lp(a) is not routinely measured, leaving millions unaware of their hidden risk.
4. What specific health risks are linked to high Lp(a)?
High levels of Lp(a) dramatically raise the risk of several serious conditions, including:
- Stroke: Increased likelihood of ischemic stroke due to clot formation.
- Cardiovascular death: Higher mortality from heart attacks and related complications.
- Major heart events: Such as myocardial infarction and need for revascularization.
- Aortic stenosis: Calcium buildup on the aortic valve.
- Peripheral artery disease: Narrowing of arteries in the legs.
Even if other cholesterol markers are normal, elevated Lp(a) alone can double or triple the risk of these outcomes. The risk is independent of LDL cholesterol, meaning it adds another layer of danger.
5. How can you find out if you have high Lp(a)?
Discovery requires a simple blood test specifically for Lp(a) measurement. It is not part of standard lipid panels (which test total cholesterol, LDL, HDL, and triglycerides). You must ask your doctor to order it, especially if you have a family history of premature heart disease, high cholesterol, or early strokes. The test is inexpensive and requires no special preparation. Given that one in five people may be affected, some experts recommend considering one-time Lp(a) screening for all adults, particularly those with other risk factors or a family history of cardiovascular disease.
6. What can be done to lower Lp(a) levels?
Currently, there are no FDA-approved therapies specifically proven to lower Lp(a) and reduce cardiovascular risk. Statins have minimal to no effect on Lp(a) levels. Lifestyle changes such as diet and exercise also have limited impact, as Lp(a) is largely genetically determined. However, emerging treatments like antisense oligonucleotides (e.g., pelacarsen) are showing promise in clinical trials by directly reducing Lp(a) production. Until these become available, the best approach is to manage other modifiable risk factors aggressively: lower LDL cholesterol, control blood pressure, quit smoking, maintain a healthy weight, and manage diabetes. This comprehensive strategy can help mitigate the overall heart risk, even if Lp(a) remains high.